{"id":15677,"date":"2022-08-03T00:00:00","date_gmt":"2022-08-03T00:00:00","guid":{"rendered":"https:\/\/cms.alj3.clients.lemonhq.io\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/"},"modified":"2026-05-12T14:12:09","modified_gmt":"2026-05-12T14:12:09","slug":"forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer","status":"publish","type":"perspectives","link":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/","title":{"rendered":"Forjar un nuevo modelo para el tratamiento del c\u00e1ncer"},"content":{"rendered":"

Republished from Abdul Latif Jameel Health Insights here<\/a>.<\/em><\/p>\n

A Q&A with Professor R Charles Coombes, newly appointed special scientific advisor to Abdul Latif Jameel Health<\/h4>\n

The latest special scientific advisor to join the Advisory Board of <\/em>Abdul Latif Jameel Health<\/em><\/a> is <\/em>Professor Charles Coombes<\/em><\/a>, a renowned world-leading authority on cancer, with a particular focus on breast cancer. \u00a0We spoke to Professor Coombes about his research, his new role at Abdul Latif Jameel Health, and his vision for the future of global healthcare.<\/em><\/p>\n

As part of its mission to accelerate access to modern quality healthcare around the world, Abdul Latif Jameel Health is continually looking to build partnerships with the leading innovators, organizations, and researchers in the global healthcare industry.<\/p>\n

\"\"

Professor Charles Coombes PhD MBBS FRCP MD FMedSci<\/p><\/div>\n

\"\"Professor R Charles Coombes is Professor of Medical Oncology, Imperial College London<\/a>, and Honorary Consultant Medical Oncologist at Imperial College Healthcare Trust<\/a>.<\/p>\n

He is also Chairman of the International Collaborative Cancer Group<\/a> \u2013 a multinational trial center (based at Imperial College London) focusing on phase II and III studies in breast cancer, among other senior roles in oncology.<\/p>\n

\"\"A keen advocate of a cross-disciplinary approach to cancer research, Professor Coombes helped to establish the Convergence Science Centre<\/a> at Imperial College in 2020.<\/p>\n

He also runs a translational laboratory which focuses on detection of micro-metastatic disease and application to the treatment of breast cancer.<\/p>\n

Could you provide a brief overview of your current work?<\/h2>\n

CC: <\/strong>One of the most important initiatives I\u2019m involved with at the moment is the Convergence Science Centre, which is a strategic partnership between Imperial College London<\/a> and The Institute of Cancer Research, London<\/a>, that was initiated around seven years ago.<\/p>\n

\"\"The aim of the program is to bring together the science expertise of Imperial College across a whole range of disciplines to help people with cancer.<\/p>\n

The most common sciences used in cancer detection and treatment are molecular and cell biology and drug discovery, but it\u2019s now widely recognized that this isn\u2019t enough.<\/p>\n

To truly make headway with this complex disease, you need to leverage the latest expertise from other scientific fields, too, such as bioengineering, mathematics, physics, population sciences, computing sciences, and so forth, which have traditionally been neglected in cancer research.<\/p>\n

This work was built on the fact that I\u2019ve spent half of my career at The Institute of Cancer Research and The Royal Marsden Hospital in London, and half my career at Imperial College.\u00a0 It seemed logical \u00a0that if we could bring together these two great institutions, both of which, combined, probably rank among the top in the UK \u2013 if not the world \u2013 in terms of cancer expertise, it could help us solve this problem.<\/p>\n

Could you explain how the Convergence Science Centre works?<\/h2>\n

CC: <\/strong>It\u2019s a sad fact that although cancer affects nearly half of us, in the West at least, it\u2019s not easy to predict which person is going to develop what cancer.\u00a0 And if cancer does develop, it\u2019s not easy to predict how the cancer is going to evolve in the human body. \u00a0This uncertainty means we can\u2019t harness new molecular treatments and diagnostic technology in the best way.\u00a0 We now have blood tests and sputum tests that can detect cancer at an extremely early stage, and blood tests that can tell you how the cancer is evolving in the patient.\u00a0 But until we have ways of enriching these technologies, we cannot refine them to be available to everyone in the world.<\/p>\n

The Convergence Science Centre helps to bring multiple scientific disciplines together to try and bridge some of these gaps in crucial areas, such as the extremely complex mathematics around genetics and DNA.<\/p>\n

What are the benefits of this approach?<\/h2>\n

CC: <\/strong>Cancer treatment in the West is based on a set of rather toxic treatments such as radiotherapy \u00a0and cytotoxic chemotherapy, and so forth.\u00a0 These are ill-defined and non-targeted technologies that as well as combating cancer, are also damaging to normal cells.\u00a0 For the \u2018global south\u2019, the aim is to sidestep these, potentially rather harmful, treatments and go straight to the latest modern diagnostic and therapeutic approaches.\u00a0 For example, artificial intelligence can define which patients need to be screened, and the type of cancer and the evolution of the cancer can all be diagnosed by\u00a0 blood tests.\u00a0 You don\u2019t need complex radiotherapy systems and large healthcare infrastructures.\u00a0 What we will need in the future are usable diagnostic technologies and targeted treatments that will enable us to avoid the sorts of damaging treatments that people have had to undergo to have their cancer treated over the last 50 years.<\/p>\n

The combination of easy diagnostics and then targeted treatment following surgery is the answer to improving the survival rate of cancer in the global south.<\/p>\n

When did you first become aware of Abdul Latif Jameel Health?<\/h2>\n

CC: <\/strong>It is a name I\u2019ve known for a while \u2013 an organization that I knew was interested in improving access to quality healthcare in emerging markets in the Middle East, Africa and Asia, which is an issue I care deeply about.\u00a0 I regularly attend conferences and I\u2019m invited to give lectures in locations across the world, particularly the MENA region, and Abdul Latif Jameel is a name that often comes up.\u00a0 So, when the opportunity arose to get involved more directly, I was keen to learn more.<\/p>\n

In your role as a special scientific advisor, what do you hope to bring to the organization?<\/h2>\n

CC: <\/strong>I\u2019m a cancer clinician and cancer scientist.\u00a0 There is a big gap between what people discover in laboratories and how it\u2019s brought into clinical use and then applied to patients.\u00a0 This gap is often ignored, because scientists are always moving on to the next thing, the next stage in their research, to constantly refine and improve what they\u2019ve done.<\/p>\n

It needs somebody like me at Imperial College to take what they\u2019ve developed and say \u201cI know you\u2019re still working on this, but what you\u2019ve got so far looks pretty good.\u00a0 There\u2019s nothing like it out there, so let\u2019s see if we can use it to help people.\u201d<\/em>\u00a0 It\u2019s what I\u2019ve been doing all my career.\u00a0 I\u2019ve been involved in developing new drugs for cancer, new diagnostic tests, mainly for breast cancer, for 40 years, and that\u2019s what I\u2019m aiming to continue doing through my role at Abdul Latif Jameel Health.<\/p>\n

Abdul Latif Jameel Health has a particular focus on improving access to healthcare in the global south. \u00a0Is this important to you?<\/h2>\n

CC: <\/strong>Yes, absolutely.\u00a0 It\u2019s an issue I\u2019m passionate about.\u00a0 For example, I\u2019ve lectured in Nigeria where there was a single cancer center with functioning equipment for the entire country of 160 million people.\u00a0 I\u2019ve been to many countries in the region where there is huge poverty, inequality, and a lack of diagnostic capability.<\/p>\n

As well as financial hurdles to overcome, there are often cultural ones, too, in terms of educating people about cancer and helping them to understand that it\u2019s not something to be ashamed of or embarrassed about.<\/p>\n

What do you see as the biggest challenges for cancer research and treatment?<\/h2>\n

CC: <\/strong>I think education is the most important thing.\u00a0 You could invest any amount of money, but without education it is only going to have a limited impact.\u00a0 The first thing to do is to educate people about illnesses and what can be done about them.\u00a0 The next priority is screening people at risk and introducing some sort of clear pathway for them to get help easily.\u00a0 To a certain degree, a lot of this could be done remotely using modern technology.\u00a0 The idea of people having to travel hundreds of miles and wait for hours in a hospital in the hope of seeing a doctor doesn\u2019t work in the modern world.<\/p>\n

One thing the COVID-19 pandemic taught us is that communication across the world is much easier than we thought.\u00a0 We should be using this to our advantage to make healthcare much more accessible in those markets that most need it.<\/p>\n

How could technologies like artificial intelligence and big data help to improve this picture?<\/h2>\n

CC: <\/strong>These kinds of technologies are hugely important to the fight against cancer, and increasingly so. Artificial intelligence (AI) is sometimes spoken of as if it\u2019s some sort of separate discipline, but it\u2019s not.\u00a0 It\u2019s already integrated within the work that \u00a0I and many cancer researchers do.<\/p>\n

Half the scientists we employ now are specialists in AI. \u00a0Not just talented mathematicians, but people who also understand genetics, biology, cancer, who can bridge these divides and bring that knowledge together.\u00a0 This is modern cancer research, and this is what the Convergence Science Centre aims to do.<\/p>\n

\"\"

Photo Credit \u00a9 Cancer Research UK Imperial Centre<\/p><\/div>\n

A single cell is probably more complex than all the computers currently available throughout the world. \u00a0Within a tiny teaspoon of blood from a cancer patient, there are more than a million fragments of DNA and RNA, all of which give information about the type of cancer they\u2019ve got and how to treat that cancer.\u00a0 But decoding that information and making it sense of it all is impossible without AI.\u00a0 Working out which sub-populations have a greater propensity to develop cancer and therefore more likely to benefit from screening is another critical area where AI is essential.\u00a0 \u00a0And then of course, there are the families with a history of cancer where AI is vital for helping us to understand the genetics of cancer predisposition.<\/p>\n

Another area where AI is essential is in terms of chemistry and target identification.\u00a0 When, for example, a blood test shows there is cancer present and that it is growing and dividing by a certain type of factor, to build a drug to inhibit that you need to know the structure of the protein that the drug is supposed to bind to, to inhibit the cancer proliferation in that particular patient.\u00a0 It\u2019s extraordinarily complex and relies on AI at virtually every stage in the journey to discover a new drug.<\/p>\n

How has the pandemic changed the narrative around global healthcare?<\/h2>\n

CC: <\/strong>I think it has changed it in two main ways.\u00a0 First, it has shown people that science can have a global impact.\u00a0 There\u2019s been a certain amount of cynicism about modern science among commentators before the pandemic, around climate change for example.\u00a0 The pandemic has shown the massively positive impact that science can have and how it can improve health outcomes for people across the globe.<\/p>\n

The second big change is that the pandemic has highlighted the inequality of healthcare between different regions of the world.\u00a0 The proportion of people in the global south who have been vaccinated is still incredibly low, for example.<\/p>\n

Within the field of cancer specifically, there is growing understanding that, in the same way that viruses evolve and change their genetics to overcome treatments, cancer does too.\u00a0 \u00a0People have become used to the idea of sequencing viruses and the same thing is true in cancer.\u00a0 You need to monitor the cancer in the patient to predict what treatments you\u2019re going to give the patient.\u00a0 That\u2019s very similar to the development of vaccines for mutated viruses.<\/p>\n

How do you hope Abdul Latif Jameel Health can help to improve this picture and address some of these challenges?<\/h2>\n

CC: <\/strong>I believe Abdul Latif Jameel Health has a fairly unique role in that it is interested in early diagnosis, and it seeks to bring the latest healthcare advances to underserved markets in the global south.\u00a0 The Butterfly iQ+ handheld ultrasound device<\/a>, for example, is an example of a technology that could make a huge difference in many markets though earlier diagnosis.<\/p>\n

\"Butterfly

The Butterfly IQ+ hand-held, whole-body ultrasound probe in action (Photo Credit \u00a9 Butterfly Network Inc.)<\/p><\/div>\n

Abdul Latif Jameel\u2019s strong legacy in the region, its knowledge, understanding and existing partnerships, can also be a great advantage in getting these technologies out into the market and overcoming some of the barriers \u2013 often cultural and practical issues as much as financial ones.<\/p>\n

Looking ahead, how optimistic are you for the future of cancer research and cancer treatment?<\/h2>\n

CC: <\/strong>I\u2019m biased, because in my area of breast cancer I\u2019ve seen the cure rate improving quite dramatically throughout my career, so in that sense I\u2019m very optimistic.\u00a0 Of course, there are still big discrepancies in breast cancer rates across the globe, but overall, I\u2019m hopeful that in 10 years we will have significantly improved the cure rate.<\/p>\n

Other cancers, like lung cancer, pancreatic cancer, brain cancer, stomach cancer for example, are very difficult to treat, partly because they are diagnosed too late.\u00a0 This is where some of these technologies around testing, screening and early diagnosis are vital.\u00a0 These could change the face of cancer treatment, particularly in the global south, if we can apply them effectively.<\/p>\n

So, I\u2019m optimistic, but it needs to be done on almost an \u2018industrial\u2019 scale rather than the piecemeal methods that have been used up to now.<\/p>\n","protected":false},"featured_media":15663,"menu_order":0,"template":"","class_list":["post-15677","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nForjar un nuevo modelo para el tratamiento del c\u00e1ncer - Abdul Latif Jameel<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Forjar un nuevo modelo para el tratamiento del c\u00e1ncer - Abdul Latif Jameel\" \/>\n<meta property=\"og:description\" content=\"Republished from Abdul Latif Jameel Health Insights here. A Q&A with Professor R Charles Coombes, newly appointed special scientific advisor to Abdul Latif Jameel Health The latest special scientific advisor to join the Advisory Board of Abdul Latif Jameel Health is Professor Charles Coombes, a renowned world-leading authority on cancer, with a particular focus on […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Abdul Latif Jameel\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T14:12:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cancer-Cells-Illustration.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1546\" \/>\n\t<meta property=\"og:image:height\" content=\"1032\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/\",\"url\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/\",\"name\":\"Forjar un nuevo modelo para el tratamiento del c\u00e1ncer - Abdul Latif Jameel\",\"isPartOf\":{\"@id\":\"https:\/\/10.0.2.222\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cancer-Cells-Illustration.jpg\",\"datePublished\":\"2022-08-03T00:00:00+00:00\",\"dateModified\":\"2026-05-12T14:12:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/#primaryimage\",\"url\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cancer-Cells-Illustration.jpg\",\"contentUrl\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cancer-Cells-Illustration.jpg\",\"width\":1546,\"height\":1032},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/10.0.2.222\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Forjar un nuevo modelo para el tratamiento del c\u00e1ncer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/10.0.2.222\/en\/#website\",\"url\":\"https:\/\/10.0.2.222\/en\/\",\"name\":\"Abdul Latif Jameel\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/10.0.2.222\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Forjar un nuevo modelo para el tratamiento del c\u00e1ncer - Abdul Latif Jameel","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"es_ES","og_type":"article","og_title":"Forjar un nuevo modelo para el tratamiento del c\u00e1ncer - Abdul Latif Jameel","og_description":"Republished from Abdul Latif Jameel Health Insights here. A Q&A with Professor R Charles Coombes, newly appointed special scientific advisor to Abdul Latif Jameel Health The latest special scientific advisor to join the Advisory Board of Abdul Latif Jameel Health is Professor Charles Coombes, a renowned world-leading authority on cancer, with a particular focus on […]","og_url":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/","og_site_name":"Abdul Latif Jameel","article_modified_time":"2026-05-12T14:12:09+00:00","og_image":[{"width":1546,"height":1032,"url":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cancer-Cells-Illustration.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"11 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/","url":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/","name":"Forjar un nuevo modelo para el tratamiento del c\u00e1ncer - Abdul Latif Jameel","isPartOf":{"@id":"https:\/\/10.0.2.222\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/#primaryimage"},"image":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cancer-Cells-Illustration.jpg","datePublished":"2022-08-03T00:00:00+00:00","dateModified":"2026-05-12T14:12:09+00:00","breadcrumb":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/#primaryimage","url":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cancer-Cells-Illustration.jpg","contentUrl":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cancer-Cells-Illustration.jpg","width":1546,"height":1032},{"@type":"BreadcrumbList","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/forjar-un-nuevo-modelo-para-el-tratamiento-del-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/10.0.2.222\/en\/"},{"@type":"ListItem","position":2,"name":"Forjar un nuevo modelo para el tratamiento del c\u00e1ncer"}]},{"@type":"WebSite","@id":"https:\/\/10.0.2.222\/en\/#website","url":"https:\/\/10.0.2.222\/en\/","name":"Abdul Latif Jameel","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/10.0.2.222\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"post-meta-fields":{"_wp_page_template":["default"],"_published_date":["field_6057129b493f5"],"published_date":["20220803"],"_location":["field_601267396ce72"],"location":["Londres, Reino Unido"],"_featured":["field_601a3b473c5c5"],"featured":["0"],"_footnotes":["field_66fd39afb9383"],"footnotes":[""],"_business_sector":["field_66f6b5bcac8cb"],"business_sector":["Salud"],"_content_series":["field_66fe3c439f8f6"],"content_series":[""],"_old_post_id":["field_66fe3fd59f8f7"],"old_post_id":["100936"],"_short_title":["field_60925d67125ef"],"short_title":["Forjar un nuevo modelo para el tratamiento del c\u00e1ncer"],"_summary":["field_6019304103a20"],"summary":["<p>Entrevista con el profesor R. Charles Coombes, recientemente nombrado asesor cient\u00edfico especial de Abdul Latif Jameel Health<\/p>"],"_mobile_featured_image":["field_66f6b4bee65f3"],"mobile_featured_image":["https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cancer-Cells-Illustration.jpg"],"_push_notification":["field_66f6b47de65f1"],"push_notification":[""],"_publish_mobile":["field_66f6b491e65f2"],"publish_mobile":["0"],"_status":["field_652694983fe12"],"status":["publish"],"_thumbnail_id":["15663"],"_wpml_word_count":["{\"total\":2253,\"to_translate\":{\"ar\":2253,\"zh-hans\":2253,\"fr\":2253,\"ja\":2253,\"es\":2253,\"tr\":2253}}"],"_last_translation_edit_mode":["native-editor"],"amazonS3_cache":["a:18:{s:83:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-Charles-Coombes-3.jpg\";a:2:{s:2:\"id\";s:5:\"15664\";s:11:\"source_type\";s:13:\"media-library\";}s:85:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-Charles-Coombes-3.jpg\";a:2:{s:2:\"id\";s:5:\"15664\";s:11:\"source_type\";s:13:\"media-library\";}s:74:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ICR-ICL-logos.jpg\";a:2:{s:2:\"id\";s:5:\"15665\";s:11:\"source_type\";s:13:\"media-library\";}s:81:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ICR-ICL-logos-300x55.jpg\";a:2:{s:2:\"id\";s:5:\"15665\";s:11:\"source_type\";s:13:\"media-library\";}s:76:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ICR-ICL-logos.jpg\";a:2:{s:2:\"id\";s:5:\"15665\";s:11:\"source_type\";s:13:\"media-library\";}s:83:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ICR-ICL-logos-300x55.jpg\";a:2:{s:2:\"id\";s:5:\"15665\";s:11:\"source_type\";s:13:\"media-library\";}s:70:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/CRUK-logo.jpg\";a:2:{s:2:\"id\";s:5:\"15666\";s:11:\"source_type\";s:13:\"media-library\";}s:77:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/CRUK-logo-300x87.jpg\";a:2:{s:2:\"id\";s:5:\"15666\";s:11:\"source_type\";s:13:\"media-library\";}s:72:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/CRUK-logo.jpg\";a:2:{s:2:\"id\";s:5:\"15666\";s:11:\"source_type\";s:13:\"media-library\";}s:79:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/CRUK-logo-300x87.jpg\";a:2:{s:2:\"id\";s:5:\"15666\";s:11:\"source_type\";s:13:\"media-library\";}s:77:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ICR-ICL-exterior.jpg\";a:2:{s:2:\"id\";s:5:\"15667\";s:11:\"source_type\";s:13:\"media-library\";}s:85:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ICR-ICL-exterior-300x195.jpg\";a:2:{s:2:\"id\";s:5:\"15667\";s:11:\"source_type\";s:13:\"media-library\";}s:79:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ICR-ICL-exterior.jpg\";a:2:{s:2:\"id\";s:5:\"15667\";s:11:\"source_type\";s:13:\"media-library\";}s:87:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ICR-ICL-exterior-300x195.jpg\";a:2:{s:2:\"id\";s:5:\"15667\";s:11:\"source_type\";s:13:\"media-library\";}s:66:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cells.jpg\";a:2:{s:2:\"id\";s:5:\"15668\";s:11:\"source_type\";s:13:\"media-library\";}s:68:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cells.jpg\";a:2:{s:2:\"id\";s:5:\"15668\";s:11:\"source_type\";s:13:\"media-library\";}s:69:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ERM_4668.jpg\";a:2:{s:2:\"id\";s:4:\"3984\";s:11:\"source_type\";s:13:\"media-library\";}s:71:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ERM_4668.jpg\";a:2:{s:2:\"id\";s:4:\"3984\";s:11:\"source_type\";s:13:\"media-library\";}}"],"_edit_lock":["1779686379:4"],"content":["<h4>Entrevista con el profesor R. Charles Coombes, recientemente nombrado asesor cient\u00edfico especial de Abdul Latif Jameel Health<\/h4>\r\n<p><em>El \u00faltimo asesor cient\u00edfico especial en unirse al Consejo Asesor de <\/em><a href=\"https:\/\/aljhealth.com\"><em>Abdul Latif Jameel Health<\/em><\/a><em> es el <\/em><a href=\"https:\/\/aljhealth.com\/en\/our-people\/professor-charles-coombes-mbbs-frcp-md-fmedsci\/\"><em>profesor Charles Coombes<\/em><\/a><em>, una reconocida autoridad en el \u00e1mbito del c\u00e1ncer a nivel mundial, que se centra sobre todo en el c\u00e1ncer de mama. Hablamos con el profesor Coombes sobre su investigaci\u00f3n, su nuevo cargo en Abdul Latif Jameel Health y su visi\u00f3n del futuro de la sanidad mundial.<\/em><\/p>\r\n<p>Como parte de su misi\u00f3n de acelerar el acceso a la atenci\u00f3n sanitaria moderna de alta calidad en todo el mundo, Abdul Latif Jameel Health busca continuamente establecer asociaciones con los principales innovadores, organizaciones e investigadores en la industria mundial de la salud.<\/p>\r\n\r\n[caption id=\"attachment_100924\" align=\"aligncenter\" width=\"1000\"]<img class=\"size-full wp-image-100924\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/08\/Prof-Charles-Coombes-3.jpg\" alt=\"\" width=\"1000\" height=\"667\" \/> Profesor Charles Coombes PhD MBBS FRCP MD FMedSci[\/caption]\r\n\r\n<p><img class=\"alignright size-medium wp-image-100910\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/08\/ICR-ICL-logos-300x55.jpg\" alt=\"\" width=\"300\" height=\"55\" \/>El profesor R. Charles Coombes es profesor de Oncolog\u00eda M\u00e9dica en el <a href=\"https:\/\/www.imperial.ac.uk\/people\/c.coombes\">Imperial College London<\/a> y asesor onc\u00f3logo m\u00e9dico honorario en <a href=\"https:\/\/www.imperial.nhs.uk\/consultant-directory\/raoul-charles-coombes\">Imperial College Healthcare Trust<\/a>.<\/p>\r\n<p><img class=\"alignleft size-medium wp-image-100903\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/08\/CRUK-logo-300x87.jpg\" alt=\"\" width=\"300\" height=\"87\" \/>Entre otros puestos s\u00e9nior en oncolog\u00eda, tambi\u00e9n es presidente del <a href=\"https:\/\/www.bigagainstbreastcancer.org\/\">International Collaborative Cancer Group<\/a>, un centro de ensayos multinacional (con sede en el Imperial College London) que se centra en estudios de fase II y III en el c\u00e1ncer de mama.<\/p>\r\n<p>El profesor Coombes, un entusiasta defensor de un enfoque interdisciplinar en la investigaci\u00f3n del c\u00e1ncer, ayud\u00f3 a establecer el <a href=\"https:\/\/www.convergencesciencecentre.ac.uk\/\">Convergence Science Centre<\/a> en 2020.<\/p>\r\n<p>Tambi\u00e9n dirige un laboratorio traslacional que se centra en la detecci\u00f3n de la enfermedad micrometast\u00e1sica y la aplicaci\u00f3n al tratamiento del c\u00e1ncer de mama.\u00a0<\/p>\r\n<h2>\u00bfPodr\u00eda hacer una breve descripci\u00f3n de su trabajo actual?<\/h2>\r\n<p><strong><img class=\"alignright size-medium wp-image-100917\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/08\/ICR-ICL-exterior-300x195.jpg\" alt=\"\" width=\"300\" height=\"195\" \/>CC: <\/strong>Una de las iniciativas m\u00e1s importantes en las que estoy involucrado en este momento es el Convergence Science Centre, que es una asociaci\u00f3n estrat\u00e9gica entre el <a href=\"https:\/\/www.imperial.ac.uk\/\">Imperial College London<\/a> y <a href=\"https:\/\/www.icr.ac.uk\/\">The Institute of Cancer Research, London<\/a>, que se inici\u00f3 hace unos siete a\u00f1os.<\/p>\r\n<p>El objetivo del programa es reunir la experiencia cient\u00edfica del Imperial College en una amplia gama de disciplinas para ayudar a las personas con c\u00e1ncer.<\/p>\r\n<p>Las ciencias m\u00e1s comunes utilizadas en la detecci\u00f3n y el tratamiento del c\u00e1ncer son la biolog\u00eda molecular y celular y el descubrimiento de f\u00e1rmacos, pero ahora se reconoce ampliamente que esto no basta.<\/p>\r\n<p>Para avanzar realmente con esta compleja enfermedad tambi\u00e9n necesitamos aprovechar la experiencia m\u00e1s reciente de otros campos cient\u00edficos, como la bioingenier\u00eda, las matem\u00e1ticas, la f\u00edsica, las ciencias de la poblaci\u00f3n, la inform\u00e1tica, etc., que tradicionalmente se han pasado por alto en la investigaci\u00f3n del c\u00e1ncer.<\/p>\r\n<p>Este trabajo se bas\u00f3 en el hecho de que he pasado una mitad de mi carrera en The Institute of Cancer Research y The Royal Marsden Hospital de Londres, y la otra en el Imperial College. Parec\u00eda l\u00f3gico que reunir a estas dos grandes instituciones, las cuales, combinadas, probablemente se encuentren entre las mejores del Reino Unido, e incluso del mundo, en t\u00e9rminos de experiencia en c\u00e1ncer, podr\u00eda ayudarnos a resolver este problema.<\/p>\r\n<h2>\u00bfPodr\u00eda explicar c\u00f3mo funciona el Convergence Science Centre?<\/h2>\r\n<p><strong>CC: <\/strong>Aunque tristemente el c\u00e1ncer afecta a casi la mitad de la poblaci\u00f3n, al menos en Occidente, no es f\u00e1cil predecir qu\u00e9 persona va a desarrollar qu\u00e9 c\u00e1ncer. Asimismo, si se desarrolla un c\u00e1ncer, tampoco es f\u00e1cil predecir c\u00f3mo va a evolucionar en el cuerpo humano. Esta incertidumbre significa que no podemos aprovechar de la mejor manera los nuevos tratamientos moleculares ni la tecnolog\u00eda de diagn\u00f3stico. Ahora tenemos an\u00e1lisis de sangre y de esputo que pueden detectar el c\u00e1ncer en una etapa extremadamente temprana, y an\u00e1lisis de sangre que pueden indicar c\u00f3mo evoluciona el c\u00e1ncer en el paciente. Sin embargo, hasta que tengamos formas de enriquecer estas tecnolog\u00edas, no podremos perfeccionarlas para que est\u00e9n disponibles para todo en el mundo.<\/p>\r\n<p>El Convergence Science Centre ayuda a reunir m\u00faltiples disciplinas cient\u00edficas para intentar salvar algunas de estas brechas en \u00e1reas cruciales, como las matem\u00e1ticas extremadamente complejas en torno a la gen\u00e9tica y el ADN.<\/p>\r\n<h2>\u00bfCu\u00e1les son los beneficios de este enfoque?<\/h2>\r\n<p><strong>CC: <\/strong>En Occidente el tratamiento del c\u00e1ncer se basa en un conjunto de tratamientos bastante t\u00f3xicos, como radioterapia y quimioterapia citot\u00f3xica, etc. Estas son tecnolog\u00edas imprecisas y no dirigidas que, adem\u00e1s de combatir el c\u00e1ncer, tambi\u00e9n da\u00f1an las c\u00e9lulas normales. Para el \u201csur global\u201d, el objetivo es eludir estos tratamientos, potencialmente m\u00e1s bien da\u00f1inos, y pasar directamente a los \u00faltimos enfoques diagn\u00f3sticos y terap\u00e9uticos modernos. Por ejemplo, la inteligencia artificial puede definir qu\u00e9 pacientes deben ser examinados y el tipo de c\u00e1ncer y su evoluci\u00f3n pueden diagnosticarse mediante an\u00e1lisis de sangre. No se necesitan sistemas de radioterapia complejos ni grandes infraestructuras sanitarias. Lo que necesitaremos en el futuro son tecnolog\u00edas diagn\u00f3sticas \u00fatiles y tratamientos dirigidos que nos permitan evitar los tratamientos da\u00f1inos a los que las personas han tenido que someterse para luchar contra el c\u00e1ncer en los \u00faltimos 50\u00a0a\u00f1os.<\/p>\r\n<p>La combinaci\u00f3n de un diagn\u00f3stico sencillo y un tratamiento dirigido despu\u00e9s de la cirug\u00eda es la respuesta para mejorar la tasa de supervivencia del c\u00e1ncer en el sur global.<\/p>\r\n<h2>\u00bfCu\u00e1ndo conoci\u00f3 Abdul Latif Jameel Health?<\/h2>\r\n<p><strong>CC: <\/strong>Es un nombre que conozco desde hace tiempo: una organizaci\u00f3n que sab\u00eda que estaba interesada en mejorar el acceso a una atenci\u00f3n sanitaria de calidad en los mercados emergentes de Oriente Medio, \u00c1frica y Asia, que es un problema que me preocupa profundamente. Asisto regularmente a conferencias y me invitan a dar charlas en lugares de todo el mundo, especialmente en la regi\u00f3n MENA, y Abdul Latif Jameel es un nombre que se menciona con frecuencia. As\u00ed que, cuando se me plante\u00f3 la oportunidad de involucrarme m\u00e1s directamente, estaba deseando aprender m\u00e1s.<\/p>\r\n<h2>\u00bfQu\u00e9 espera aportar a la organizaci\u00f3n en su funci\u00f3n como asesor cient\u00edfico especial?<\/h2>\r\n<p><strong>CC: <\/strong>Soy especialista cl\u00ednico y cient\u00edfico en c\u00e1ncer. Existe una gran brecha entre lo que las personas descubren en los laboratorios y c\u00f3mo se introduce en el uso cl\u00ednico para aplicarlo a los pacientes. A menudo se ignora, porque los cient\u00edficos siempre est\u00e1n pensando en la siguiente etapa de su investigaci\u00f3n, para perfeccionar y mejorar constantemente sus resultados.<\/p>\r\n<p>Hace falta que alguien como yo en Imperial College tome lo que han desarrollado y diga: <em>\u201cS\u00e9 que todav\u00eda est\u00e1s trabajando en esto, pero lo que tienes hasta ahora tiene muy buena pinta. No hay nada similar en el mercado, as\u00ed que veamos si podemos usarlo para ayudar a la gente\u201d.<\/em> Llevo haciendo esto a lo largo de toda mi carrera. He participado en el desarrollo de nuevos f\u00e1rmacos y nuevas pruebas diagn\u00f3sticas para el c\u00e1ncer, principalmente de mama, durante 40 a\u00f1os, y eso es lo que quiero seguir haciendo a trav\u00e9s de mi funci\u00f3n en Abdul Latif Jameel Health.<\/p>\r\n<h2>Abdul Latif Jameel Health se centra especialmente en mejorar el acceso a la atenci\u00f3n sanitaria en el sur global. \u00bfEsto es importante para usted?<\/h2>\r\n<p><strong>CC: <\/strong>Sin duda. Es un problema que me apasiona. Por ejemplo, he dado conferencias en Nigeria, donde hab\u00eda un \u00fanico centro oncol\u00f3gico con equipos funcionales para todo un pa\u00eds de 160\u00a0millones de personas. He estado en muchos pa\u00edses de la regi\u00f3n donde hay una gran pobreza, desigualdad y falta de capacidad diagn\u00f3stica.<\/p>\r\n<p>Adem\u00e1s de los obst\u00e1culos financieros, a menudo tambi\u00e9n hay trabas culturales a la hora de educar a las personas sobre el c\u00e1ncer y ayudarles a comprender que no es algo de lo que avergonzarse.<\/p>\r\n<h2>\u00bfCu\u00e1les considera que son los mayores desaf\u00edos para la investigaci\u00f3n y el tratamiento del c\u00e1ncer?<\/h2>\r\n<p><strong>CC: <\/strong>Creo que la educaci\u00f3n es lo m\u00e1s importante. Podr\u00edamos invertir cualquier cantidad de dinero, pero sin educaci\u00f3n solo tendr\u00e1 un impacto limitado. Lo primero que hay que hacer es educar a las personas sobre las enfermedades y lo que se puede hacer al respecto. La siguiente prioridad es examinar a las personas en riesgo e introducir un camino claro para que puedan obtener ayuda f\u00e1cilmente. En cierta medida, gran parte de esto podr\u00eda hacerse de forma remota utilizando tecnolog\u00eda moderna. En el mundo moderno, la idea de que las personas tengan que viajar cientos de kil\u00f3metros y esperar horas en un hospital con la esperanza de ver a un m\u00e9dico no funciona.<\/p>\r\n<p>Una cosa que nos ense\u00f1\u00f3 la pandemia de COVID-19 es que la comunicaci\u00f3n en todo el mundo es mucho m\u00e1s f\u00e1cil de lo que pens\u00e1bamos. Deber\u00edamos aprovechar esto para lograr que la atenci\u00f3n sanitaria sea mucho m\u00e1s accesible en los mercados que m\u00e1s la necesitan.<\/p>\r\n<h2>\u00bfC\u00f3mo podr\u00edan tecnolog\u00edas como la inteligencia artificial y el big data ayudar a mejorar esta situaci\u00f3n?<\/h2>\r\n<p><strong>CC: <\/strong>Este tipo de tecnolog\u00edas son muy importantes para la lucha contra el c\u00e1ncer, y cada vez m\u00e1s. A veces la inteligencia artificial (IA) se considera una disciplina independiente, pero no lo es. Ya est\u00e1 integrada en el trabajo que hacemos yo y muchos otros investigadores del c\u00e1ncer.<\/p>\r\n<p>La mitad de los cient\u00edficos que empleamos ahora son especialistas en IA. No son solo expertos en matem\u00e1ticas, sino profesionales que tambi\u00e9n comprenden la gen\u00e9tica, la biolog\u00eda y el c\u00e1ncer, por lo que pueden salvar las brechas y unir esos conocimientos. En eso consiste la investigaci\u00f3n moderna sobre el c\u00e1ncer, que es lo que pretende hacer el Convergence Science Centre.<\/p>\r\n\r\n[caption id=\"attachment_100896\" align=\"aligncenter\" width=\"1912\"]<img class=\"size-full wp-image-100896\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/08\/Cells.jpg\" alt=\"\" width=\"1912\" height=\"843\" \/> Cr\u00e9dito de la fotograf\u00eda \u00a9 Cancer Research UK Imperial Centre[\/caption]\r\n\r\n<p>Una sola c\u00e9lula es probablemente m\u00e1s compleja que todos los ordenadores disponibles actualmente en todo el mundo. En una peque\u00f1a cucharadita de sangre de un paciente con c\u00e1ncer hay m\u00e1s de un mill\u00f3n de fragmentos de ADN y ARN, que proporcionan informaci\u00f3n sobre el tipo de c\u00e1ncer y c\u00f3mo tratarlo. No obstante, descodificar y darle sentido a esta informaci\u00f3n ser\u00eda imposible sin la IA. Determinar qu\u00e9 subpoblaciones tienen una mayor propensi\u00f3n a desarrollar c\u00e1ncer y, por lo tanto, m\u00e1s probabilidades de beneficiarse de los ex\u00e1menes es otra \u00e1rea cr\u00edtica donde la IA es esencial. Por supuesto, tambi\u00e9n est\u00e1n las familias con antecedentes de c\u00e1ncer. Aqu\u00ed la IA es vital para ayudarnos a comprender la gen\u00e9tica de la predisposici\u00f3n al c\u00e1ncer.<\/p>\r\n<p>Otra \u00e1rea en la que la IA es fundamental es en t\u00e9rminos de qu\u00edmica e identificaci\u00f3n de objetivos. Por ejemplo, si un an\u00e1lisis de sangre muestra que hay c\u00e1ncer presente, que est\u00e1 creciendo y dividi\u00e9ndose por un determinado tipo de factor, para construir un f\u00e1rmaco que inhiba la proliferaci\u00f3n del c\u00e1ncer en ese paciente en particular es necesario conocer la estructura de la prote\u00edna a la que el f\u00e1rmaco deber\u00eda unirse. Descubrir un nuevo f\u00e1rmaco es extraordinariamente complejo y requiere la IA en pr\u00e1cticamente todas las etapas.<\/p>\r\n<h2>\u00bfC\u00f3mo ha cambiado la pandemia la narrativa respecto a la atenci\u00f3n sanitaria global?<\/h2>\r\n<p><strong>CC: <\/strong>Creo que la ha cambiado de dos maneras principales. En primer lugar, ha demostrado a la gente que la ciencia puede tener un impacto global. Antes de la pandemia hab\u00eda cierto cinismo sobre la ciencia moderna, por ejemplo, en relaci\u00f3n con el cambio clim\u00e1tico. La pandemia ha demostrado el impacto masivamente positivo que puede tener la ciencia y su capacidad de mejorar los resultados sanitarios para personas de todo el mundo.<\/p>\r\n<p>El segundo gran cambio es que la pandemia ha puesto de relieve la desigualdad en la atenci\u00f3n sanitaria entre diferentes regiones del mundo. Por ejemplo, en el sur global la proporci\u00f3n de personas que han sido vacunadas sigue siendo incre\u00edblemente baja.<\/p>\r\n<p>En el campo del c\u00e1ncer en concreto, cada vez se comprende m\u00e1s que, igual que los virus evolucionan y cambian su gen\u00e9tica para superar los tratamientos, el c\u00e1ncer tambi\u00e9n lo hace. Las personas se han acostumbrado a la idea de secuenciar virus y lo mismo ocurre con el c\u00e1ncer. Debemos controlar el c\u00e1ncer en el paciente para predecir qu\u00e9 tratamientos hemos de administrarle. Esto es muy similar al desarrollo de vacunas para virus mutados.<\/p>\r\n<h2>\u00bfC\u00f3mo espera que Abdul Latif Jameel Health ayude a mejorar esta imagen y abordar algunos de estos desaf\u00edos?<\/h2>\r\n<p><strong>CC: <\/strong>Creo que Abdul Latif Jameel Health tiene un papel bastante \u00fanico, ya que est\u00e1 interesado en el diagn\u00f3stico temprano y trata de llevar los \u00faltimos avances sanitarios a mercados desfavorecidos en el sur global. El dispositivo ecogr\u00e1fico port\u00e1til <a href=\"https:\/\/alj.com\/en\/perspective\/democratizing-healthcare-scan-by-scan\/\">Butterfly iQ+<\/a> es un ejemplo de una tecnolog\u00eda que podr\u00eda marcar una gran diferencia en muchos mercados gracias a un diagn\u00f3stico m\u00e1s temprano.<\/p>\r\n\r\n[caption id=\"attachment_94230\" align=\"aligncenter\" width=\"2560\"]<img class=\"size-full wp-image-94230\" src=\"https:\/\/alj.com\/app\/uploads\/2021\/11\/ERM_4668.jpg\" alt=\"Butterfly Network\" width=\"2560\" height=\"1707\" \/> La sonda de ultrasonidos de cuerpo entero port\u00e1til Butterfly IQ+ en acci\u00f3n (Cr\u00e9dito de la fotograf\u00eda \u00a9 Butterfly Network Inc.)[\/caption]\r\n\r\n<p>El s\u00f3lido legado de Abdul Latif Jameel en la regi\u00f3n, su conocimiento, su comprensi\u00f3n y las asociaciones existentes tambi\u00e9n pueden ser una gran ventaja para sacar estas tecnolog\u00edas al mercado y superar algunas de las barreras, que a menudo son tanto problemas culturales y pr\u00e1cticos como financieros.<\/p>\r\n<h2>De cara al futuro, \u00bfhasta qu\u00e9 punto es optimista para el futuro de la investigaci\u00f3n y el tratamiento del c\u00e1ncer?<\/h2>\r\n<p><strong>CC: <\/strong>No soy imparcial. En mi \u00e1rea del c\u00e1ncer de mama he visto c\u00f3mo la tasa de curaci\u00f3n mejoraba de forma bastante dr\u00e1stica a lo largo de mi carrera, as\u00ed que en ese sentido soy muy optimista. Por supuesto, todav\u00eda hay grandes discrepancias en las tasas de curaci\u00f3n del c\u00e1ncer de mama en todo el mundo, pero en general, espero que en 10\u00a0a\u00f1os las hayamos mejorado significativamente.<\/p>\r\n<p>Otros tipos de c\u00e1ncer, como, por ejemplo, el c\u00e1ncer de pulm\u00f3n, de p\u00e1ncreas, de cerebro o de est\u00f3mago, son muy dif\u00edciles de tratar, en parte porque se diagnostican demasiado tarde. Para ellos son fundamentales las tecnolog\u00edas en torno a las pruebas, el cribado y el diagn\u00f3stico temprano. Si fu\u00e9semos capaces de aplicarlas de forma eficaz, podr\u00edamos revolucionar los tratamientos contra el c\u00e1ncer, especialmente en el sur global.<\/p>\r\n<p>As\u00ed que soy optimista, pero deber\u00edamos trabajar casi a escala \u201cindustrial\u201d, en lugar de con los m\u00e9todos fragmentados que se han utilizado hasta ahora.<\/p>"],"_content":[""],"_ame_cpe_post_policy":["{\"accessProtection\":{\"active\":\"replace\"}}"],"_edit_last":["22"],"_wpml_media_duplicate":["1"],"_wpml_media_featured":["1"],"_yoast_wpseo_content_score":["30"],"_yoast_wpseo_estimated-reading-time-minutes":["11"]},"_links":{"self":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/perspectives\/15677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/media\/15663"}],"wp:attachment":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/media?parent=15677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}